SAKK 15/19

Study SAKK 15/19 Radiation of lung tumor and maintenance therapy with durvalumab following treatment with chemotherapy and durvalumab in patients with advanced small cell lung cancer

Summary of the study

In this study, patients with small cell lung cancer (SCLC) in whom the disease has already spread are being examined. It is being investigated whether radiotherapy of the tumor together with the administration of the drug Durvalumab: - can slow down the progression of the disease - and whether this therapy is safe. The active substance durvalumab stimulates the body's own immune system to fight the tumor cells more effectively and is therefore known as immunotherapy. The additional radiation could strengthen this effect. Durvalumab is currently approved in Switzerland for the treatment of another form of lung cancer (non-small cell lung cancer). This is a national study being conducted at several hospitals in Switzerland. It is planned that 46 patients will take part in the study. The study treatment will last a maximum of two years and three months per study participant. In the following two years, the participants will be monitored regularly.

(BASEC)

Further study information

Further Studies: Lung cancer

Recruitment completed

SAKK 16/18

Immunotherapy and radiotherapy in stage III non-small cell lung cancer

SAKK LuCa 2

Registry and study of EGFR-mutated NSCLC

salVage

Phase III randomized controlled trial comparing maintenance systemic therapy alone with systemic therapy plus local ablative treatment for patients with advanced stage IV non-small cell lung cancer

ETOP CHESS

A multicentre single arm phase II trial assessing the efficacy of radical immunotherapy and chemotherapy, stereotactic radiotherapy and surgery in patients with synchronous oligo-metastatic NSCLC

Study 22615

A Phase 3 study of BAY 2927088 compared to standard treatment in advanced non-small cell lung cancer (NSCLC) with HER2 mutations. Study 22615 ("SOHO-02")

Recruitment completed

ACHILES

ACHILES Does immunotherapy improve survival in patients with small cell lung cancer with limited disease who have received chemotherapy and radiotherapy?

ETOP ADOPT

An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

ETOP RAISE

A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer. RAISE: Niraparib added to anti-PD-L1 antibody maintenance in SLFN11-positive, extensive-disease SCLC

Recruitment completed

SAKK 19/17

Study SAKK 19/17 - Durvalumab in patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC) and inadequate general condition - A multicenter single-arm phase II study.